Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Merck & Co., Inc. (MRK) Q2 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q2 2024 Earnings Conference Call July 30, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean L...
Merck second quarter tops Street view on strong Keytruda sales
Merck & Co posted higher-than-expected second-quarter results on Tuesday on strong growth of its blockbuster cancer immunotherapy Keytruda, the world's best-selling prescription medicine.
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and va...
Merck's RSV drug meets main goals of mid-to-late stage trial
Merck said on Tuesday its respiratory syncytial virus (RSV) drug met the safety and efficacy goals in a mid- to late- stage study testing it in infants.
Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
Deutsche Bank Has 4 Sizzling ‘Fresh Money' Dividend Stock Picks for Q3
24/7 Insights With the S&P 500 up 15% year-to-date, a correction could be coming in the third quarter.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
China grants licence to Merck's KEYTRUDA for stomach cancer treatment
China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemor...
Merck Stock Edges Higher on FDA Vaccine Approval
The U.S. Food and Drug Administration (FDA) approved Merck & Co Inc's (NYSE:MRK) next-generation vaccine to protect adults against the pneumococcal disease.
US FDA approves Merck's pneumococcal vaccine for adults
Merck said on Monday the U.S. Food and Drug Administration has approved its next-generation vaccine to protect adults against pneumococcal disease.
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia ...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease & Pneumococcal Pneumonia in Adults.
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent E...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA Plus Chemotherapy as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma.
Related Companies